ASGIN1: A Potential Drug Target for Cell Growth, Differentiation and Inflammation

Target Name: LINC00632

NCBI ID: G286411

LINC00632

ASGIN1: A Potential Drug Target for Cell Growth, Differentiation and Inflammation

LINC00632 (ASINC) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target for various diseases.

ASGIN1, the encoded gene for LINC00632, was identified in a gene expression study using RNA sequencing technology. The ASGIN1 gene has four exons, and the protein it encodes has seven transmembrane domains and a cytoplasmic tail. It is located on chromosome 18q21.

Expression of ASGIN1 has been observed in a variety of tissues and organs, including the brain, heart, and kidneys. It is expressed in the brain at levels of around 10% of the total protein in brain tissue, and in the heart and kidneys at levels of around 5% and 10% of the total protein, respectively.

ASGIN1 has been shown to play a role in several biological processes, including cell growth, differentiation, and inflammation. It is a positive regulator of the TGF-β pathway, which is a well-established regulator of cell growth and differentiation. TGF-β signaling is involved in the development and maintenance of tissues and organs, and is a target for many diseases, including cancer.

In addition to its role in TGF-β signaling, ASGIN1 has also been shown to play a role in the regulation of cell adhesion. It is a negative regulator of the cadherin protein, which is a major regulator of cell adhesion in tissues and organs. ASGIN1 has been shown to interact with cadherin and prevent its from functioning, which would normally promote cell adhesion. This interaction between ASGIN1 and cadherin suggests that ASGIN1 may be a potential drug target for diseases that are characterized by disrupted cell adhesion, such as cancer.

ASGIN1 has also been shown to play a role in the regulation of inflammation. It is a negative regulator of the nuclear factor kappa B (NFKB), which is a well-established regulator of inflammation. NFKB signaling is involved in the regulation of many inflammatory processes, including inflammation, pain, and inflammation-related diseases. ASGIN1 has been shown to prevent NFKB from functioning, which would normally promote inflammation. This interaction between ASGIN1 and NFKB suggests that ASGIN1 may be a potential drug target for diseases that are characterized by inflammation, such as rheumatoid arthritis or inflammatory bowel disease.

Despite its potential as a drug target, ASGIN1 has not yet been shown to be involved in any diseases. Further research is needed to determine the exact role of ASGIN1 in biology and to explore its potential as a drug target.

In conclusion, LINC00632 (ASGIN1) is a protein that has been identified as a potential drug target for various diseases due to its role in cell growth, differentiation, and inflammation. Further research is needed to determine the exact function of ASGIN1 and to explore its potential as a drug target.

Protein Name: Long Intergenic Non-protein Coding RNA 632

The "LINC00632 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00632 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets